Analysis
Six IPO storylines moved this week, and the spread between them is the more useful signal than any single deal:
- [Ligent Technologies](/pulse/ligent-technologies-727m-hong-kong-ipo-debut-2026) -- $727M Hong Kong IPO, popped as much as 19.2% intraday on real, profitable AI-datacenter revenue.
- [Bamboo Insurance](/pulse/bamboo-insurance-halts-ipo-2026) -- pulled its ~$3.24B all-secondary offering on the day it was set to price.
- [ADARx Pharmaceuticals](/pulse/adarx-pharmaceuticals-upsized-ipo-priced-2026) -- priced an upsized $446.3M IPO at the top of its range with AbbVie buying in directly.
- [NSE India](/pulse/nse-india-ipo-debut-trading-2026) -- 5.7x oversubscribed, but closed its debut only 1.8% above issue price.
- [Firmus Grid](/pulse/firmus-5b-australia-ipo-asx-2026) -- disclosed a $77M forecast loss ahead of an up-to-$60B valuation ask.
- [Oura](/pulse/oura-ipo-eli-lilly-profitability-2026) -- revealed it's actually profitable, with Eli Lilly seeking up to $100M of shares.
“- Bamboo Insurance -- pulled its ~$3.24B all-secondary offering on the day it was set to price.”
The pattern that emerges from laying these six side by side: strong revenue quality (Ligent, ADARx, Oura) produced strong pricing or strong debuts, while deals asking investors to underwrite a bigger gap between story and current financials (Bamboo's pricing-day pull, Firmus's disclosed loss) hit resistance or produced only muted enthusiasm. NSE India sits in between -- a dominant, profitable company whose oversubscribed book didn't translate into first-day conviction, a reminder that even strong fundamentals don't guarantee a pop once a deal is this large and well-covered going in.
What this cohort argues against is treating "the IPO window" as a single macro variable that's either open or closed. Six deals, similar weeks, similar broad-market backdrop, and six outcomes that tracked each company's own revenue quality and disclosure more closely than any shared market condition. The next real test comes when SB Energy actually launches its long-pending US roadshow, per Bloomberg's reporting -- a $439 billion contracted backlog against near-term losses of its own, the same tension now playing out at Firmus.